Literature DB >> 15231830

Novel mechanism of inhibition of HIV-1 reverse transcriptase by a new non-nucleoside analog, KM-1.

Louise Z Wang1, George L Kenyon, Kenneth A Johnson.   

Abstract

2-Naphthalenesulfonic acid (4-hydroxy-7-[[[[5-hydroxy-6-[(4 cinnamylphenyl)azo]-7-sulfo-2-naphthalenyl]amino]-carbonyl]amino]-3-[(4-cinnamylphenyl)]azo (KM-1)) is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) that was designed to bind at an unconventional site on human immunodeficiency virus type 1 reverse transcriptase (RT) (Skillman, A. G., Maurer, K. W., Roe, D. C., Stauber, M. J., Eargle, D., Ewing, T. J., Muscate, A., Davioud-Charvet, E., Medaglia, M. V., Fisher, R. J., Arnold, E., Gao, H. Q., Buckheit, R., Boyer, P. L., Hughes, S. H., Kuntz, I. D., and Kenyon, G. L. (2002) Bioorg. Chem. 30, 443-458). We have investigated the mechanism by which KM-1 inhibits wild-type human immunodeficiency virus type 1 RT by using pre-steady state kinetic methods to examine the effect of KM-1 on the parameters governing the single nucleotide incorporation catalyzed by RT. Analysis of the pre-steady-state burst phase of dATP incorporation showed that KM-1 decreased the amplitude of the reaction as previously shown for other NNRTIs, because of the slow equilibration of the inhibitor with RT. In the ternary enzyme-DNA-KM-1 complex (E-DNA-I), incorporation of the next nucleotide onto the primer is blocked. However, unlike conventional NNRTIs, the inhibitory effect was caused primarily by weakening the DNA binding affinity and displacing DNA from the enzyme. Wild-type RT binds a 25/45-mer DNA duplex with an apparent K(d) of 3 nm, which was increased to 400 nm upon saturation with KM-1. Likewise, the apparent K(d) for KM-1 binding to RT increased at higher DNA concentrations. We therefore conclude that KM-1 represents a new class of inhibitor distinct from nevirapine and related NNRTIs. KM-1 can bind to RT in both the absence and presence of DNA but weakens the affinity for DNA 140-fold so that it favors DNA dissociation. The data suggest that KM-1 distorts RT conformation and misaligns DNA at the active site.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15231830     DOI: 10.1074/jbc.M406241200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

1.  N348I in HIV-1 reverse transcriptase can counteract the nevirapine-mediated bias toward RNase H cleavage during plus-strand initiation.

Authors:  Mia J Biondi; Greg L Beilhartz; Suzanne McCormick; Matthias Götte
Journal:  J Biol Chem       Date:  2010-06-08       Impact factor: 5.157

2.  The N348I mutation at the connection subdomain of HIV-1 reverse transcriptase decreases binding to nevirapine.

Authors:  Matthew M Schuckmann; Bruno Marchand; Atsuko Hachiya; Eiichi N Kodama; Karen A Kirby; Kamalendra Singh; Stefan G Sarafianos
Journal:  J Biol Chem       Date:  2010-09-27       Impact factor: 5.157

3.  Probing nonnucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by transient kinetic analyses.

Authors:  Qing Xia; Jessica Radzio; Karen S Anderson; Nicolas Sluis-Cremer
Journal:  Protein Sci       Date:  2007-08       Impact factor: 6.725

4.  Identification of mechanistically distinct inhibitors of HIV-1 reverse transcriptase through fragment screening.

Authors:  Jennifer La; Catherine F Latham; Ricky N Tinetti; Adam Johnson; David Tyssen; Kelly D Huber; Nicolas Sluis-Cremer; Jamie S Simpson; Stephen J Headey; David K Chalmers; Gilda Tachedjian
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-18       Impact factor: 11.205

5.  A new strategy to inhibit the excision reaction catalysed by HIV-1 reverse transcriptase: compounds that compete with the template-primer.

Authors:  Carlos Cruchaga; Elena Anso; María Font; Virginia S Martino; Ana Rouzaut; Juan J Martinez-Irujo
Journal:  Biochem J       Date:  2007-07-01       Impact factor: 3.857

6.  Carbonyl J acid derivatives block protein priming of hepadnaviral P protein and DNA-dependent DNA synthesis activity of hepadnaviral nucleocapsids.

Authors:  Yong-Xiang Wang; Yu-Mei Wen; Michael Nassal
Journal:  J Virol       Date:  2012-07-11       Impact factor: 5.103

Review 7.  Hepatitis B virus reverse transcriptase - Target of current antiviral therapy and future drug development.

Authors:  Daniel N Clark; Jianming Hu
Journal:  Antiviral Res       Date:  2015-09-25       Impact factor: 5.970

Review 8.  Active site and allosteric inhibitors of the ribonuclease H activity of HIV reverse transcriptase.

Authors:  Angela Corona; Takashi Masaoka; Graziella Tocco; Enzo Tramontano; Stuart F J Le Grice
Journal:  Future Med Chem       Date:  2013-12       Impact factor: 3.808

Review 9.  Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors.

Authors:  Nicolas Sluis-Cremer; Gilda Tachedjian
Journal:  Virus Res       Date:  2008-03-26       Impact factor: 3.303

10.  Biochemical mechanism of HIV-1 resistance to rilpivirine.

Authors:  Kamalendra Singh; Bruno Marchand; Devendra K Rai; Bechan Sharma; Eleftherios Michailidis; Emily M Ryan; Kayla B Matzek; Maxwell D Leslie; Ariel N Hagedorn; Zhe Li; Pieter R Norden; Atsuko Hachiya; Michael A Parniak; Hong-Tao Xu; Mark A Wainberg; Stefan G Sarafianos
Journal:  J Biol Chem       Date:  2012-09-06       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.